humanized

Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E IgE)

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

Ocaratuzumab (AME-133v) is an Fc-engineered antibody and humanized monoclonal antibody targeting CD20 (Kd≈100 pM), exhibiting antibody-dependent cellular cytotoxicity (ADCC) in chronic lymphocytic leukemia.

Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting GD2 with antitumor activity, used to study neuroblastoma, osteosarcoma, and other GD2-positive cancers.

Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5

Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR with potential anticancer activity that blocks EGFR activation and downstream signaling for the study of non-small cell lung cancer.

Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

Mepolizumab (SB 240563) is a humanized monoclonal antibody that neutralizes IL-5, and can be utilized in research on severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

Recombinant Humanized Type III Collagen 30-40kDa is an innovative biomaterial with anticancer properties. It can activate discoidin domain receptor 1 (DDR1), thereby inhibiting cancer cell autophagy, proliferation, and migration, while inducing apoptosis.

Humanized anti-tac (HAT) binding peptide is a peptide that specifically binds to the Fc region of HAT. HAT is a humanized monoclonal antibody targeting the low-affinity p55 subunit of the interleukin IL-2 receptor. The peptide can be utilized in the development of affinity chromatography media for the purification of specific monoclonal antibodies.

Recombinant Humanized Type III Collagen 28.6kDa is a synthesized form of humanized Type III collagen with a molecular weight of 28.6kDa. Known as rhCOLIII, it serves multiple biological functions, such as enhancing skin extracellular matrix regeneration and improving the cellular microenvironment. It inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen is involved in cell adhesion, migration, proliferation, and differentiation through interactions with integrins.

Recombinant humanized type III collagen (MW 55900) is a recombinant humanized collagen protein, with a molecular weight of 55900 Da, that offers diverse biological functions, such as enhancing skin extracellular matrix regeneration and improving the cellular microenvironment. This compound inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen plays a role in cell adhesion, migration, proliferation, and differentiation through interactions with integrins.

Recombinant Humanized Type XVII Collagen is a transmembrane protein that forms hemidesmosomes. It facilitates interactions between stem cells, surrounding cells, and the extracellular matrix, thereby regulating skin homeostasis, aging, and wound healing. Additionally, Recombinant Humanized Type XVII Collagen has distinct cell adhesion sites and signal transduction capabilities, which can modulate cell migration, proliferation, and differentiation.

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

Sacituzumab is a humanized IgG1 monoclonal antibody utilized in the synthesis of antibody-active small-molecule couplings (naked antibody to Sacituzumab govitecan). It exhibits potential antitumor activity and is employed in tumor research.

Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).

Bococizumab(PF-04950615) is a humanized mAb against PCSK9 and an inhibitor of the synthesis of PCSK9 in the liver that reduces the amount of low-density lipoprotein cholesterol (LDL-C) in the blood.Bococizumab is used to treat hypercholesterolemia.

Tezepelumab (AMG 157) is a humanized monoclonal antibody (IgG2λ) targeting TSLP that prevents TSLP from interacting with its heterodimer receptor. Tezepelumab can be used to study advanced asthma disease.

Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.

Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.

Human IgG1 kappa, Isotype Control is a humanized IgG-like monoclonal antibody and an isotype control antibody for human IgG1κ.

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Bevacizumab, a humanized monoclonal antibody, specifically and with high affinity binds to all isoforms of VEGF-A.